Covid19: Why aren’t you buying all doses; when will you disburse 50% of doses to states; what is the rationale for differential pricing: SC to Centre·April 30, 2021
Plea filed in SC seeking directions to Centre to issue compulsory licenses for patents on Remdesivir, Favipiravir, Tocilizumab·April 29, 2021
Bombay HC directs Centre to decide representation seeking ‘compulsory licenses’ to two patented anti-TB drugs·March 10, 2021
Patent and Patient Rights in COVID-19: Is the Right to Exclusivity a Hamlet Question?·October 8, 2020
Statement by Indian Civil Society: Need for open innovation and knowledge sharing for COVID-19 healthcare through Indian IP laws·June 24, 2020
